Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.
Rajneesh Nath, MD, a medical oncologist with Banner Health, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia (AML) population. His findings were presented at the 2021 Transplantation & Cellular Therapy Meetings.
According to Nath, the 2 most common types of stem cell transplantation are myeloablation and reduced intensity. Myeloablation is associated with increased intensity of chemotherapy and higher doses of radiation. This tends to increase the toxicity of treatment for the patient.
Nath’s hypothesis that delivery of Iomab-B directly to where it is needed can help reduce toxicity and save critical organs such as the heart, lungs and kidney. The study found that Iomab-B was able to spare the gastrointestinal tract. According to Nath, instances of sepsis in the Iomab-B group was 4% while in the standard of care group, it was 13%.